Compare Freshworks Inc (FRSH) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs McKesson Corporation — how do they compare? Freshworks Inc trades at $10.79 (market cap $2.93B), while McKesson Corporation trades at $827 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 31.8× Freshworks Inc's market cap, and McKesson Corporation pays a 0.41% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | MCK | |
|---|---|---|
Market Cap | $2.93B | $93.23B |
Sector | Technology | Health |
52-Week High | $14.77 | $995.69 |
52-Week Low | $6.88 | $659.01 |
Enterprise Value | $2.19B | $97.87B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.47, down 3.32% on the day, with a bullish technical signal from moving averages. The company shows a strong fundamental turnaround, achieving profitability in 2025 with a net income margin of 20.69% and robust revenue growth from $498M in 2022 to $839M in 2025. Recent news highlights a strategic pivot to its employee experience (EX) business and new AI product launches, with the Q2 2026 earnings report scheduled for August 4, 2026.
The outlook is positive, supported by a profitable growth trajectory, a 50% analyst buy rating, and a significant valuation discount to software peers. Key risks include execution of the EX pivot, competitive pressures in SaaS, and the need to sustain high gross margins. The stock offers opportunity as a value play with accelerating fundamentals, but faces typical growth stock volatility.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
